JP2014509662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509662A5 JP2014509662A5 JP2014502901A JP2014502901A JP2014509662A5 JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5 JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014502901 A JP2014502901 A JP 2014502901A JP 2014509662 A5 JP2014509662 A5 JP 2014509662A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- monoclonal antibody
- use according
- skin inflammation
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470538P | 2011-04-01 | 2011-04-01 | |
| US61/470,538 | 2011-04-01 | ||
| PCT/US2012/031803 WO2012135812A2 (en) | 2011-04-01 | 2012-04-02 | Treatment for dermatological pathologies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145710A Division JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509662A JP2014509662A (ja) | 2014-04-21 |
| JP2014509662A5 true JP2014509662A5 (enExample) | 2015-05-21 |
| JP6062918B2 JP6062918B2 (ja) | 2017-01-18 |
Family
ID=46927554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502901A Expired - Fee Related JP6062918B2 (ja) | 2011-04-01 | 2012-04-02 | 皮膚科的病理の治療 |
| JP2016145710A Expired - Fee Related JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016145710A Expired - Fee Related JP6453278B2 (ja) | 2011-04-01 | 2016-07-25 | 皮膚科的病理の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20120251548A1 (enExample) |
| EP (2) | EP3417879A1 (enExample) |
| JP (2) | JP6062918B2 (enExample) |
| KR (3) | KR102326482B1 (enExample) |
| CN (2) | CN110201157A (enExample) |
| AU (2) | AU2012236106B2 (enExample) |
| CA (1) | CA2831126C (enExample) |
| DK (1) | DK2694107T3 (enExample) |
| ES (1) | ES2697056T3 (enExample) |
| PT (1) | PT2694107T (enExample) |
| WO (1) | WO2012135812A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159976A2 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis treatment |
| CN103153340A (zh) | 2010-08-23 | 2013-06-12 | 埃克斯生物科技公司 | 对肿瘤疾病的治疗 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| DK2694107T3 (en) * | 2011-04-01 | 2018-12-10 | Xbiotech Inc | TREATMENT OF DERMATOLOGICAL DISORDERS |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| KR20150064091A (ko) * | 2012-10-04 | 2015-06-10 | 엑스바이오테크, 인크. | 정신의학적 병태의 치료법 |
| CN110382001A (zh) | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
| CA3179228A1 (en) * | 2020-04-16 | 2021-10-21 | Janssen Biotech, Inc. | Treatment of hidradenitis suppurativa |
| CA3095675A1 (en) * | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| WO1994008624A2 (en) | 1992-10-14 | 1994-04-28 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9405021D0 (en) * | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| US5945576A (en) * | 1996-04-05 | 1999-08-31 | Brigham & Women's Hospital, Inc. | Mouse model of psoriasis |
| US20040086507A1 (en) | 2000-10-19 | 2004-05-06 | Kenya Shitara | Antibody inhibiting vplf activity |
| JP4450644B2 (ja) | 2003-03-03 | 2010-04-14 | 日本化薬株式会社 | Ａｍｆ類を有効成分とする医薬製剤 |
| US8957056B2 (en) | 2004-05-25 | 2015-02-17 | Sloan-Kettering Instiute For Cancer Research | Migrastatin analogs in the treatment of cancer |
| US20050276807A1 (en) * | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| EP2114443A4 (en) * | 2006-12-29 | 2011-08-10 | Abbott Lab | IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY |
| US8034337B2 (en) * | 2008-05-30 | 2011-10-11 | Xbiotech, Inc. | Interleukin-1α antibodies |
| AU2009291536B2 (en) * | 2008-09-12 | 2012-08-16 | Xbiotech Inc. | Targeting pathogenic monocytes |
| SG172855A1 (en) * | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
| CN103328511B (zh) * | 2010-09-10 | 2016-01-20 | 埃派斯进有限公司 | 抗-IL-1β抗体及其使用方法 |
| DK2694107T3 (en) * | 2011-04-01 | 2018-12-10 | Xbiotech Inc | TREATMENT OF DERMATOLOGICAL DISORDERS |
| JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
-
2012
- 2012-04-02 DK DK12765366.5T patent/DK2694107T3/en active
- 2012-04-02 ES ES12765366T patent/ES2697056T3/es active Active
- 2012-04-02 WO PCT/US2012/031803 patent/WO2012135812A2/en not_active Ceased
- 2012-04-02 US US13/437,159 patent/US20120251548A1/en not_active Abandoned
- 2012-04-02 CA CA2831126A patent/CA2831126C/en active Active
- 2012-04-02 KR KR1020207036672A patent/KR102326482B1/ko not_active Expired - Fee Related
- 2012-04-02 CN CN201910233038.6A patent/CN110201157A/zh active Pending
- 2012-04-02 EP EP18186590.8A patent/EP3417879A1/en not_active Withdrawn
- 2012-04-02 EP EP12765366.5A patent/EP2694107B1/en active Active
- 2012-04-02 KR KR1020197021295A patent/KR20190090046A/ko not_active Ceased
- 2012-04-02 CN CN2012800140133A patent/CN103442733A/zh active Pending
- 2012-04-02 JP JP2014502901A patent/JP6062918B2/ja not_active Expired - Fee Related
- 2012-04-02 PT PT12765366T patent/PT2694107T/pt unknown
- 2012-04-02 AU AU2012236106A patent/AU2012236106B2/en not_active Ceased
- 2012-04-02 KR KR1020137028813A patent/KR102004554B1/ko not_active Expired - Fee Related
-
2016
- 2016-07-25 JP JP2016145710A patent/JP6453278B2/ja not_active Expired - Fee Related
- 2016-08-31 US US15/252,477 patent/US9902769B2/en active Active
-
2017
- 2017-02-22 AU AU2017201201A patent/AU2017201201B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509662A5 (enExample) | ||
| CY2023005I2 (el) | Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων | |
| CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
| NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| HK1200714A1 (en) | Fgfr-binder-active agent conjugates | |
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
| UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| IL240731B (en) | An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment | |
| PH12019500441A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| IL236892B (en) | A combination of an immunoconjugate and an antibody for use in medical treatment, a pharmaceutical preparation and a kit containing it | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| EP2797942A4 (en) | COMPOSITION OF NOVEL CARBOHYDRATE MEDICINE FOR THE TREATMENT OF HUMAN DISEASES | |
| JP2010222367A5 (enExample) | ||
| JP2015531396A5 (enExample) | ||
| HUE043355T2 (hu) | LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében | |
| IN2015DN00450A (enExample) | ||
| WO2014012094A3 (en) | Tetracycline compounds for treating neurodegenerative disorders | |
| JP2015530399A5 (enExample) | ||
| PH12015500746A1 (en) | Benzamides | |
| EP4424323A3 (en) | Anti-folr1 immunoconjugate dosing regimens | |
| EP2703488A4 (en) | COMPOSITION TO PREDICT SENSITIVITY TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS AND METHODS THEREFOR |